Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Montebello, Oslo.
Breast Cancer Res Treat. 1990 Nov;17(1):45-50. doi: 10.1007/BF01812683.
One-hundred and seventy patients with estrogen receptor positive (greater than or equal to 10 pmol/g protein) advanced breast cancer have been treated in a prospective randomized study either with continuous tamoxifen 30 mg x 1 daily (TAM), or with TAM 30 mg x 1 daily for 8 weeks alternating with medroxyprogesterone acetate 500 mg x 2 daily for 8 weeks (TAM/HD-MPA). The response rate was 62% in the group treated with cyclic TAM/HD-MPA versus 41% in the TAM alone group (p = 0.02). There was no significant difference in duration of remissions or survival.
170例雌激素受体阳性（大于或等于10 pmol/g蛋白质）的晚期乳腺癌患者参与了一项前瞻性随机研究，他们被分为两组，一组接受持续每日一次30 mg他莫昔芬（TAM）治疗，另一组接受每日一次30 mg他莫昔芬治疗8周，之后交替每日两次500 mg醋酸甲羟孕酮治疗8周（TAM/HD-MPA）。接受TAM/HD-MPA周期治疗组的缓解率为62%，而单纯TAM治疗组为41%（p = 0.02）。缓解持续时间或生存率无显著差异。
